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EFFICACY OF FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS 
WITH CROHN’S DISEASE 
CHRISTOPHER MALLARD 
ABSTRACT 
Crohn’s disease (CD) affects 1.5 million Americans a year.  Many patients 
refractory to standard treatments suffer from life-long detrimental symptoms that reduce 
quality of life.  Chronic inflammation of the gastrointestinal tract, a hallmark of CD, has 
led to the development of drugs and interventions targeting the immune response.  Recent 
ideology regarding the pathophysiology of CD has implicated a role for the microbiome 
within the human gut.  The advent of metagenomics has allowed for the characterization 
of the microbiome of both healthy and diseased individuals.  The phylogenetic bacterial 
makeup of the microbiome of patients with CD shows an alteration from that of healthy 
individuals.  Therapeutic methods incorporating the re-establishment of a healthy 
microbiome are being investigated.  Fecal microbiota transplantation (FMT) has become 
the “gold standard” of care for patients afflicted with Clostridium difficile (C. diff.) 
infection who do not respond to a standard antibiotic regimen.  C. diff.-infection presents 
with similar symptoms and alterations of the microbiome to that observed in patients 
diagnosed with CD.  To date, only studies of three case and two cohorts utilizing FMT in 
patients with CD have been reported.   Results from these studies show potential 
usefulness for fecal microbiota transplantation as a therapy for CD. This review offers 
insight for improved clinical trials in which FMT and immune response therapies are 
adjunctively utilized to improve CD treatment. 
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INTRODUCTION 
Crohn’s disease (CD) is an idiopathic, chronic inflammatory bowel disease (IBD) 
of the gastrointestinal (GI) tract of genetically susceptible individuals.  It can range 
anywhere from the mouth to the anus and most commonly presents with diarrhea, 
abdominal pain, rectal bleeding and in more severe cases, ulcers (Klapproth, 2012).  
Approximately 1.5 million Americans are afflicted with CD (Ananthakrishnan, 2015).  It 
exerts a major burden on an individual’s quality of life due to life-long treatments, 
frequent hospitalizations, and adverse social functioning.  There is no known etiology of 
the disorder, although understanding of factors involved in its onset has vastly improved 
in the past thirty years.   
Recent research has implicated a combination of genetic and environmental 
factors in the development of CD.  Of the genetic factors, several risk loci have been 
elucidated as prominent sites of mutation within the CD community including the 
nucleotide-binding oligomerization domain containing 2 (NOD2) and ATG16L1 genes 
(Ek, 2014).  The gene products function to regulate gut immunity but through wholly 
different mechanisms.  In addition, recent evidence has implicated the alteration of the 
gut microbiota as crucial to the onset of CD.  Certain phenotypic changes to the makeup 
of this microbial population have led to disease states and morbidity (Jacobs & Braun, 
2014).   
Chronic inflammation of the GI tract is the underlying cause of CD symptoms.  
Traditional treatments for CD include the use of immunosuppressants, steroids, and 
antibiotics with the goal of remission of inflammatory flare-ups in the short and long term 
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(Bandzar, 2013).  Many aims of research have worked to produce drugs that reduce or 
abrogate these inflammatory pathways.  Cytokines and adhesion molecules are major 
mediators of the inflammatory response and have recently been targeted for inhibition by 
experimental drugs (Pedersen, 2014).  Drugs, such as infliximab and adalimumab, 
function to inhibit the pro-inflammatory cytokine tumor necrosis factor alpha (TNF-α) 
while natalizumab targets adhesion molecules of vessel walls. Additional therapies 
targeting the microbiome include prebiotics and probiotics.  These biologic therapies aim 
to improve the overall health of an individual’s gut.  While many of these therapeutic 
options can be successful treatments in alleviating symptoms, the need for therapies that 
achieve prolonged and even complete remission of Crohn’s disease is still the focus of 
many researchers.   
Fecal microbiota transplantation (FMT) has been shown to be a successful mode 
of therapy in cases of recurrent Clostridium difficile infections (CDI) in which dysbiosis 
of the microbiome occurred (Cammarota, 2014).  Recent studies have reported an 86% 
curative rate of CDI for patients receiving multiple FMTs (Lee et al., 2014).  Due to the 
increasing evidence of positive outcomes for CDI patients, FMT has been sought as a 
therapeutic means for the two major IBD’s, Crohn’s disease and ulcerative colitis (UC).   
There are limited publications on fecal microbiota transplantation in IBD cases, 
Crohn’s disease in particular.  Much research on gastrointestinal disorders is now 
focusing on the microbiome and its interactions with the host immune system.  This 
review aims to discuss the risk factors for CD, current and experimental treatment 
options, historically successful results of fecal transplantation and its potential efficacy in 
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the treatment of Crohn’s disease. 
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PUBLISHED LITERATURE  	  
Genetic Risk Factors 
 It has been shown that relatives of patients with Crohn’s disease experience 
increased risk of developing the disease than control populations (Calkins, 1986).  This 
supports the notion that there is a genetic aspect of CD.  In the past 15 years, 163 risk loci 
have been identified as potential indicators for CD.  Many of these risk loci are shared 
amongst other disease states including, but not limited to, ulcerative colitis, ankylosing 
spondylitis, psoriasis, and even diabetes (Jostins et al., 2012).  Table 1 details the 30 loci 
that have been identified as specific to CD including NOD2 and ATG16L1.   
The NOD2 gene product has been implicated in association with Crohn’s Disease 
patients (Hugot et al., 2001).  Single nuclear polymorphisms (SNP’s) and frameshift 
mutations of the coding region of NOD2 affect the leucine-rich region of the NOD2 
receptor, a Nod-Like Receptor (NLR), which is present on antigen-presenting cells 
(APCs) and Paneth cells of the gut (Lala et al., 2003).  Recent studies have shown that 
muramyl dipeptide (MDP), a component of the peptidoglycan layer of the cell wall of 
many bacterial cells, serves as the major ligand for the NOD2 receptor (Inohara et al., 
2003).  Normal function of these receptors stimulate NF-κΒ (nuclear factor kappa-light-
chain-enhancer of activated B cells), a transcription factor that rapidly initiates pro-
inflammatory responses (Baldwin, 1996).  Compromised function of these immune 
response genes could lead to uncontrolled, and potentially damaging inflammation, which  
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*Gray highlighting indicates newly discovered loci.  Bolded rs numbers represent SNP’s with p-
values less than 1 X 10-13.  Bold genes represent verification with 2 or more sequencing 
techniques (Taken from Jostins et al., 2012).  
TABLE 1: Crohn’s disease Specific Risk Loci 	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may explain the susceptibility of patients with mutant NOD2 loci for chronic CD.  Co-
stimulation with Toll-like receptor 4 (TLR-4), another molecule known to activate NF- 
κΒ, has also been shown to enhance both pro- and anti-inflammatory cytokine production 
(Fritz et al., 2005).  It is believed that regulating inflammation is an extremely important 
function that helps to maintain gut immunity, and dysfunction of these receptors has the 
capacity to allow for translocation of commensal bacteria across the mucosal-epithelial 
barrier.  Displacement of intestinal microbes from the confines of the gut, where they are 
recognized as non-threatening, to the tissue is likely to induce robust inflammatory 
responses characteristic of those observed in patients with compromised NOD2 function.  
In addition, many researchers believe the NOD2 receptor plays a role in immune-
regulatory mechanisms that act to suppress TLR activation of pro-inflammatory 
cytokines (Watanabe, 2004).  Having compromised abilities to regulate inflammatory 
responses in the gut could lead to enhanced recruitment of inflammatory cells and 
subsequent tissue damage.  Figure 1 illustrates TLR and NOD2 co-stimulation leading to 
an inflammatory response.  The NOD2 receptor is contained within the NLRP family in 
the figure, associating with caspases to induce the release of inflammatory signaling 
molecules.  Whether polymorphisms of the NOD2 gene are causal or resultant in patients 
with CD is still unclear.  Further investigation into the implications of mutated NOD2 
and their association with the development and life-long persistence of CD will elucidate 
possible treatment strategies to correct for compromised regulation of intestinal 
inflammation.   
	   7 
Another mechanism by which many researchers believe a chronic inflammatory 
state is sustained in the gut is the disruption of normal autophagic pathways in innate 
immune cells.  Autophagy has been established as a means for phagocytic cells, such as 
macrophages and dendritic cells, to sample cytosolic material from pattern recognition 
receptors (PRR’s) and effectively clear them via lysozomal degradation (Tal & Iwasaki, 
2009).  ATG16L1 is a gene linked to autophagy and has been identified as an important 
risk locus for CD.  ATG16L1 T300A mutation in a murine model has been shown to 
reduce antimicrobial autophagy as well as increase Interleukin-1 beta (IL-1β) secretion of 
innate immune cells of the lamina propria (Lassen et al., 2014).  IL-1β induces 
inflammation as shown in Figure 1, and has been implicated as a mediator of intestinal 
epithelial barrier function, increasing permeability with increased expression levels (Al-
Sadi & Ma, 2007).  Therefore, targeting IL-1β in CD patients may help dampen intestinal 
inflammation and alleviate the painful flare-ups caused by uncontrolled innate immune 
responses.   
Genetic predisposition to Crohn’s Disease does not necessarily lead to onset of 
disease.  However, elucidation of risk loci and subsequent gene products that can become 
dysfunctional allows for further research into the mechanisms that can result in CD.  
Dysfunction of receptors essential to the inflammatory response (NOD2) or autophagic 
(ATG16L1) pathways of immune cells of the gut allows for potential dysregulation and 
onset of CD. 
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Figure 1: Co-stimulation between TLR and NOD2 receptors resulting in production and secretion 
of IL-1β and a pro-inflammatory response (Taken from Kasper, 2013). 
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 Environmental Factors 
 
 The pathophysiology of IBD is not well understood.  While many persons with 
risk variants present with the clinical symptoms of CD, most do not and live healthy 
lives.  Microbiota-host interactions are a symbiotic relationship.  Unhealthy diet can lead 
to colonization of microbes within the gut that are not beneficial to the host, potentially 
inducing inflammatory responses.  As a westernized diet, one of high fat and sugar 
content, becomes more consumable throughout the world, the incidence of CD and other 
inflammatory bowel diseases has increased (Ananthakrishnan, 2015).  Consequently, 
rapid growth and expansion of what was typically a European and North American 
disease to a more world-wide patient base lends to the notion that environmental 
influences, not solely genetic risk factors, are paramount to the onset of CD.  Factors such 
as a westernized diet and lack of exercise have been targeted as potential warning signs 
for disease or flare-ups, however, it is the alteration of an individual’s microbiome 
population that has spurred most interest over the past decade (O’Toole, 2014).   
 
Microbiome and Inflammatory Bowel Disorders 
 The human gut microbiome encodes for thousands of bacterial species that inhabit 
the gastrointestinal tract of all human beings.  They thrive in a symbiotic relationship 
with the host as either commensal or mutualistic bacteria (Hold et al., 2014). The Human 
Microbiome Project, commissioned by the National Institute of Health, has used 
advances in sequencing technologies and metagenomics in order to map the genome of 
the microbiota of healthy individuals.  The purpose of the project is to establish a 
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documented “healthy cohort” of genetic information which would be used to compare the 
microbiota populations of persons affected by various diseases with those of healthy 
individuals (Hold et al., 2014).  Knowing which microbial populations are most 
beneficial and in what combination, will facilitate treatment regimens to help restore the 
communities that are most beneficial to the well being of the host. 
The term, “dysbiosis” refers to the alteration of an individual’s microbiome, and 
is usually accompanied by a disease-state.  Immune cells within the host intestine tolerate 
homeostatic intestinal microbes.  Drastic changes in microbial populations to unfamiliar 
species may provoke inflammatory responses, leading to the characteristic flare-ups 
experienced by patients diagnosed with CD.  In the last decade it has been shown that the 
gut of healthy individuals contains a large volume of bacteria of the phyla Firmicutes and 
Bacteroidetes (Frank et al., 2007).  These two phyla have been shown to decrease in 
number in individuals who have been diagnosed with CD creating a dysbiotic 
environment between the host and microbial population.  In addition, bacteria of the 
phyla Proteobacteria are more abundant in these patients (Mukhopadhya, 2012).  Figure 
2 is a representation of phyla-level classification of patients who underwent ilio-colic 
resection surgery and post-operative colonoscopy versus healthy controls.  From this 
particular study, it can be seen that both Firmicutes and Bacteroidetes dominate both the 
ileum and colon of healthy individuals while Proteobacteria are more prevalent amongst 
those with CD.  Furthermore, lack of diversity of bacterial species amongst the different 
phyla has been identified as a condition of CD patients.  Manichanh et al. (2006) reported 
	   11 
a reduction from 43 ribotypes of Firmicutes in healthy patients to just 13 in those 
afflicted with CD.   
While it has been established that a dysbiotic gut is a hallmark of CD, it is still 
unknown whether this is a cause of the disorder or simply a result of already persisting 
inflammation, possibly due to mutations in loci known to control inflammatory pathways.  
How the innate immune system of the gut reacts to changes in the microbiota is a popular 
field of interest to researchers, as it is the key to subduing damaging inflammatory 
reactions that plague many patients diagnosed with CD and other inflammatory bowel 
disorders. 
 
Diet and Crohn’s disease 
 When discussing the microbiome as an indicator for Crohn’s disease one must 
also discuss any means that contains the potential to alter the makeup of the microbiome.  
Most studies examining the correlation of diet with CD have been retrospective in nature, 
and no definitive link has been established.  However, diet possesses the ability to 
contribute to the pathogenesis of IBD and must be extensively researched in a controlled 
setting.  Studies of how healthy individuals with CD respond to various changes in 
controlled diet could elucidate the mechanisms of intestinal immune tolerance.   
Fiber has been implicated as an important nutrient in maintaining proper gut 
health.  It has been shown to decrease permeability of Escherichia coli across M-cells of 
Peyer’s patches of the gut (Roberts et al., 2010).  Fiber is also broken down to short-chain 
fatty acids (SCFA), which have been known to regulate inflammation of the gut by  
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Phylogenetic Microbiome Classification Post-Operation 
 
 
Figure 2: Phyla-level classification of the microbiome of both the (A) ileum and (B) colon of 
patients with CD undergoing resection surgery and post-operative colonoscopy versus healthy 
individuals undergoing surgery and colonoscopy.  Prevalence of phylum decreasing from top to 
bottom (Taken from Dey, 2013) 
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inhibiting certain nuclear factors that actively stimulate pro-inflammatory cytokines 
(Maslowski, 2011).  Studies investigating SCFA’s have determined a role for increasing 
immune tolerance by increasing the production of regulatory T-cells in the gut, which are 
capable of countering pro-inflammatory cytokine secretion (Thorburn, 2014).  A 
retrospective study of 59 CD patients compared to 477 controls showed an increased 
dietary intake of sugars amongst the CD population (Jakobsen, 2013).  Another 
independent study of 168 children, of which 53 had CD, confirmed that the children with 
CD had an increased dietary intake of sugars and meats (Tsiountsioura et al., 2014).  
These results highlight the risks of high sugar-containing diets and suggest they result in 
colonization of threatening microbes within the gut, which stimulate inflammatory 
reactions from intestinal immune cells.  Substituting the high sugar diet with one high in 
fiber may sweep away damaging microbes and activate regulatory T cells that hinder 
inflammation, thereby restoring intestinal homeostasis and relieving patients of flare-ups. 
Dietary vitamins have also been associated with a lower incidence of IBD due to 
their anti-inflammatory properties.  Both vitamin D and calcium are thought to enhance 
the resistance to epithelial cell dysfunction and injury.  The hormonally activated form of 
vitamin D, 1,25(OH)2 D3, has been proven to ameliorate the effects of certain helper T-
cells (TH 1 and TH 17) known to induce and maintain inflammatory reactions (Cantorna, 
2014).  Patients with Crohn’s disease display a chronic proliferation of TH 1 and TH 17, 
which produce pro-inflammatory cytokines.  The vitamin D receptor on these cells is 
only accessible in the activated T-cells that would be indicative of disease (Cantorna, 
2014).  These are encouraging data that support a role for vitamin D as a beneficial 
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participant in an anti-inflammatory response of the gut, and suggest it could be utilized to 
abrogate damaging intestinal inflammation associated with CD.   
Certain amino acids are thought to be immunoregulatory in function as well.  
Glutamine and arginine have been found to mediate inflammation during times of stress 
and flare-ups.  Glutamine is the preferred substrate of enterocytes of the intestine, and 
recent enteral nutritional intervention studies have observed a therapeutic result of such 
supplementation (Coëffier, 2010).  Similarly, L-arginine supplementation in a murine 
model displayed reduced serum levels of TNF-α and IL-17, two constitutively elevated 
cytokines during bouts of inflammation (Ren et al., 2014).  Supplemental diets and 
therapies of arginine and glutamine can be advantageous towards achieving clinical 
remission of CD flare-ups. 
The advent of metagenomic sequencing has allowed for the classification of the 
gut microbiome in healthy and diseased individuals.  Insights into how the manipulation 
and alteration of the microbiome can affect healthy individuals have potential to inspire 
development of novel therapeutics for patients with CD.  
 
Current Management 
 Due to the unknown etiology of Crohn’s disease and the variation by which it 
presents from patient to patient, managing the disease focuses on alleviating symptoms 
and inhibiting a wide range of inflammatory molecules.  Symptoms include chronic flare-
ups, diarrhea, weight loss, and abdominal pain to name a few.	  	  Anti-inflammatory 
antibody therapies target TNF-α and alpha-4 integrin molecules to suppress 
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inflammation.  More recently, cytokine specific antibodies are being researched as 
another means to achieve remission of inflammation.  Immunosuppresants, such as 
Azathioprine and Mercaptopurine function to suppress the immune response and have 
been utilized in organ transplantation and inflammatory disorders for decades.  
Approaches targeting the microbiota have been gaining ground in the scientific 
community as a means to abrogate possible pathogenic stimuli in the gut and resolve a 
dysbiotic environment.  These include antibiotics, probiotics, prebiotics, and fecal 
microbiota transplantation.  Other therapies focus on supplementing much needed 
nutrition into the diet.  Exclusive enteral nutrition (EEN) is a therapy that temporarily 
suspends 80-90% of a patient’s normal diet for a liquid supplement enriched with 
beneficial nutrients and a majority of the daily caloric intake (Day & Burgess, 2013).  It 
has been extensively studied and shown to induce remission in CD patients (Takagi et al., 
2006).  All of these therapies offer certain advantages and disadvantages to the patient.  
Providing a personalized regimen that is effective at achieving remission while 
minimizing detrimental effects to the patient is the goal of CD management. 
 
Anti-inflammatory Drugs 
TNF-α is an inflammatory cytokine that is secreted from helper T-cells, TH 1 
cells chiefly among them (Romagnani, 1994).  Its presence in CD patients has been well 
documented.  While this cytokine contains pleiotropic properties and affects many 
different organ systems, the entirety of its importance is still not completely understood.  
Therapeutic agents targeting TNF-α have been successful in reducing inflammation 
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within the bowel.  Such agents include infliximab, adalimumab, and certolizumab pegol.  
Infliximab is a IgG1 murine-human monoclonal antibody that binds to the precursor of 
TNF-α, essentially inhibiting its differentiation and activity (Ebert, 2009).  It also 
functions in the cell- signaling cascade of TNF-α.  TNF-α receptor type 2 (TNFR2) 
binding to its ligand cleaves off the extracellular domain and enters the circulation as a 
soluble product.  Infliximab increases cleavage of TNFR2 from innate immune cells 
reducing its presence on the surface and tying up the TNF-α (Reinhard, 1997).  
Adalimumab is another TNF-α blocker that binds directly to TNF-α and 
neutralizes its biological activity.  It is also pro-apoptotic to mononuclear cells producing 
TNF-α (Cvetković, 2006).  In a retroactive analysis of 124 patients administering 
adalimumab self-injections, 75% were satisfied with the results of the treatment while 
85% continued to adhere to the treatment (Hirai et al., 2014).  In 2008, certolizumab 
pegol was approved for Crohn’s disease patients who did not respond well to either 
infliximab or adalimumab.  Certolizumab pegol is a humanized antibody that has a 
polyethylene glycol (PEG)ylated fragment that binds and inhibits TNF-α (Nesbitt et al., 
2007).  It has been suggested that certolizumab pegol would be a good alternative to other 
anti-TNF-α drugs for pregnant women.  The polyethylene glycol does not cross the 
placental barrier protecting the child from unnecessary complications (Pasut, 2014).   
A meta-analysis screened 506 studies using anti-TNF-alpha therapies and 
reported on 10 randomized-controlled studies using infliximab, adalimumab, and/or 
certolizumab pegol in the treatment of CD (Stidham et al., 2014).  Endpoints included 
induction of remission and response as well as maintenance of remission and response.  
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All 3 anti-TNF-­‐α agents were successful in significantly inducing and maintaining 
remission and response compared to placebo controls.  Anti-TNF-α agents were 1.66 
times more likely to induce clinical remission and 1.68 times more likely to maintain 
clinical remission in CD patients.   
The advantages of TNF-­‐α inhibitors are clear.  Clinical remission of flare-ups has 
been well documented.  Certain complications including targeting of antibody to 
particularly inflamed regions of the bowel have been encountered.  In patients who do not 
respond well to the therapy, endoscopic and serological results have indicated an inability 
of the anti-TNF-α antibody to migrate to diseased tissues (Yarur et al., 2015).  In 
addition, infliximab resistance has been found in some patients with CD in which 
doubling the dose or reducing the dose had no particular effect on clinical recurrence or 
remission rates (Nagata et al., 2015).  It is also implicated in the increased risk of post-
operative complications (El-Hussuna, 2014), however, there are conflicting views as to 
the validity of these claims. 
Alternative to anti-TNF-α inhibitors, natalizumab is a humanized monoclonal 
antibody that targets alpha-4 integrin molecules of both innate and adaptive immune 
cells.  Alpha-4 integrin is expressed on basophils, eosinophils, monocytes and 
lymphocytes.  One ligand for this molecule is the vascular cell adhesion molecule-1 
(VCAM-1).  VCAM-1 is expressed on the endothelial cells of blood vessels.  Upon 
stimulation with various pro-inflammatory cytokines, VCAM-1 is expressed in order to 
assist innate and adaptive immune cells in migrating across endothelial cells to the sites 
of inflammation (Schechner, 1999).  Natalizumab binds to alpha-4 integrin and inhibits it 
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from binding VCAM-1 (Wipfler et al., 2011).  In doing so, natalizumab inhibits the 
migration of immune cells to sites of inflammation, dampening the inflammatory 
response that occurs during flare-ups in CD patients.  One benefit of natalizumab is that 
alpha-4 integrin is not expressed on neutrophils.  These innate immune cells can continue 
to phagocytically clear microbial and bacterial fragments, thus preserving an immune 
response (Hickey, 2009).  In a recent study, 49 CD patients who had previously seen no 
beneficial returns on anti-TNF-α treatment were administered natalizumab for a 
minimum 7-month duration.  Eighty-five percent of patients found success with the 
treatment lasting at least 12 months (Sakuraba et al., 2013).   
The use of biological agents, including TNF-α and alpha-4 integrin targeting 
drugs, has vastly improved the quality of life of many patients suffering from CD.  Table 
2 illustrates the various drugs that target molecules of the inflammatory response as well 
as certain immune cell populations that are elevated in CD.  Brodalumab and tocilizumab 
are experimental drugs that target pro-inflammatory cytokines IL-17R and IL-6R, 
respectively.  Abatacept does not target inflammatory molecules but instead attempts to 
inhibit the production of T-cells that would produce such molecules in response to 
antigen.  With all the advances that have been made in the field, there is still 20-40% of 
patients who do not respond to these therapies (Nielsen, 2012).  Prominence of the role of 
the microbiota in CD has been gaining traction over the years.  For this reason, it is 
paramount that adjunctive therapies targeting the microbiome be investigated 
concurrently with anti-inflammatory treatments. 
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Table 2: Common drugs and their target effects in treating inflammation in CD patients (Taken 
from Bandzar, 2013) 
        Cellular pathways and contraindications. 
 Drug Cellular pathway 
Infliximab Block TNF-alpha 
Adalimumab Block TNF-alpha 
Certolizumab pegol Block TNF-alpha 
Natalizumab Block alpha-4 integrin 
Human growth hormone Block IL-6 
Conjugated linoleic acid Up-regulate PPAR-gamma 
Rifaximin Inhibit bacterial transcription 
Ustekinmumab Block p40 subunit of IL-23, IL-12 
AMG 139 Block IL-23 
Brodalumab Block IL-17R 
Tocilizumab Block IL-6R 
IL-10 Block IL-6, TNF-alpha, IFN-gamma 
IL-11 Preserve intestinal morphology 
Visilizumab Induce apoptosis in T-cells 
Abatacept Block T-cell activation 
Mesenchymal stem cells (MSCs) 
Block CD80/86, IL-12, TNF-alpha, and increase IL-
10 
. 
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Microbiota Treatments  
 The dysbiosis of the gut microbiome has been implicated as a possible 
pathogenesis of CD and has led to the advent of many therapies aimed at re-establishing 
the symbiotic relationship between microbiota and host consistent with that of a healthy 
individual.  The use of antibiotics has been found to yield conflicting results, with a great 
many trials resulting in a lack of efficacy.  Prolonged antibiotic use has also been 
implicated with various side effects.  Unlike antibiotics, probiotics are living bacterial 
organisms that are ingested in large amounts in order to re-establish gut homeostasis and 
provide health benefits to the host.  They must be either pathogenic towards inflammation 
inducing microbes or outcompete these same harmful bacteria for valuable nutrients and 
space (Gionchetti et al., 2006).  	  
Antibiotics 
 Metronidazole is an antimicrobial that inhibits nucleic acid synthesis of anaerobic 
bacterial cells.  It has historically been utilized as a treatment against CD as far back as 
1978 (Blichfeldt, 1978).  In this double blind cross-over study, 22 CD patients receiving 
steroids were treated with either metronidazole or placebo for 2 months.  No significant 
difference was found in overall clinical condition between the 2 groups, however, 
patients with colonic disease were found to have improved symptoms.  Sutherland et al. 
(1991) also found mixed results in a study of 105 patients who were treated with different 
doses of metronidazole.  The Crohn’s disease activity index (CDAI) showed 
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improvement from baseline in patients on the metronidazole regimen.  A CDAI score of 
less than 150 is considered remission.  Clinical remission was not achieved in the groups 
being treated with metronidazole.   
 Ciprofloxacin has been studied in conjunction with and independent of 
metronidazole.  In a study of 47 adults with CD, ciprofloxacin was administered 500mg 
twice daily against a placebo group receiving no treatment.  While mean CDAI scores 
were not significant, patients in the ciprofloxacin group achieved remission with a mean 
score of 112 (Arnold, 2002).  In another study, metronidazole and ciprofloxacin were 
administered together while the placebo group received a standard therapy of 
methylprednisolone, a steroid.  Remission rates of the treatment group and placebo group 
were 63% and 45.5%, respectively (C. Prantera et al., 1996).  This indicated a possible 
alternative to steroidal treatment. 
 More recently, rifaximin has been studied for its efficacious potential in CD 
patients.  Rifaximin has no known drug-drug interactions and is non-systemic leading 
many to suggest a favorable role in the treatment of CD (Charmot, 2012).  In a study of 
402 patients, rifaximin was administered in doses of 400mg, 800mg, or 1200mg twice 
daily for 12 weeks (Prantera et al., 2012). Significant results were seen in the cohort that 
received 800mg treatment while the 400mg and 1200mg groups were not found to be 
significantly different from the placebo control.  In addition, adverse events (AE) were 
noted predominantly in the 1200mg group ranging from nausea and vomiting to fever and 
increased C-reactive protein sera levels.  Ten percent of patients in this group ceased the 
treatment before the endpoint due to these AE’s.   
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 The use of antibiotics to treat CD is a double-edged sword.  Prolonged use of 
antibiotics in clinical settings has been implicated in the induction of Clostridium difficile 
infection in patients with otherwise healthy microflora (Theriot, 2014).  The idea that 
antibiotics can induce disruptions in the normal microbiota as well as remedy them limits 
its potential as an ideal treatment for CD. 
 
Pre- and Probiotics 
 The ever-growing notion that the microbiota plays a role in the pathogenesis of 
IBD has spurred research into the use of probiotics and prebiotics as a means to treat CD.  
The idea of probiotics was first proposed by Nobel prize winner Elie Metchnikoff who 
believed that Lactobacilli in the gut could confer health and longevity to humans 
(Keszthelyi et al., 1996).  Lactobacilli and Bifidobacteria are among the first bacterial 
phyla to colonize the GI tract of humans prenatally (Reuter, 2001).  They confer 
homeostatic and immune related health benefits to the gut, chiefly, their antimicrobial 
property.  Many lactobacilli and bifidobacteria strains are effective at resisting 
colonization of harmful, pathogenic bacteria including Escherichia coli and 
Pseudomonas aeruginosa (Presti et al., 2015).  In vitro analysis of immune-regulatory 
function of certain probiotic strains showed an ability to modulate cytokine secretion of a 
human fibroblast cell-line of the gut (Presti et al., 2015).  Figure 3 shows the ability of 
some lactobacillus strains to inhibit pro-inflammatory cytokine secretion.  Another 
bacterial strain that has recently been found to be beneficial to the gut is 
Faecalibacterium prausnitzii.  Its advantage as a probiotic lies in its ability to up-regulate 
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regulatory T-cells in a murine model (Qiu, 2013).  These T-cells suppress inflammation 
by secreting anti-inflammatory cytokines such as IL-10 and TGF-β1.   
Ten randomized-controlled trials (RCT) were found in which CD was treated 
using probiotics only (Ghouri et al., 2014).  Lactobacillus, Lactobacillus rhamnosis and 
Lactobacillus johnsonii were the bacterial strains used in these studies.  Endpoints of the 
trials included clinical remission with CDAI score below 150, endoscopic recurrence 
rate, and clinical relapse rate.  All three Lactobacillus strains did not significantly lower 
CDAI scores or relapse rates (Shen, 2009).  Saccharomyces boulardii	  is another probiotic 
that has been studied for its potential benefit.  In a murine model study, Saccharomyces 
boulardii was shown to improve enteric barrier defense by decreasing permeability of 
epithelial cells (Garcia Vilela et al., 2008).  A cohort of 20 CD patients suffering from 
diarrhea and abdominal pain took part in a randomized, double-blinded study to evaluate 
S. boulardii against a placebo control (Plein, 1993).  A decreased frequency in bowel 
movements was observed in the intervention group for up to 10 weeks, however, relapse 
occurred in all patients past this point.   
Unlike probiotics, prebiotics are not considered “live microorganisms”, however, 
they are selectively fermented nutrients that possess the ability to feed healthy bacteria of 
the GI tract.  Two randomized controlled studies tested for clinical remission of CD with 
2 different prebiotics, fructo-oligosaccharides (FOS) and lactulose, respectively.  FOS 
has been shown to increase fecal bifidobacteria as well as attenuate pro-inflammatory 
cytokine production in a murine model (Yeh, 2014).  In a study of 49 controls and 54 CD 
patients, CD patients were administered 15g/day FOS while controls received placebo 
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Figure 3: Effect of lactobacilli and bifidobacteria strains on TNF-α (black bar) and IL-4 (gray 
bar) secretion by gut fibroblast cells in the presence of sodium dodecyl sulfate (irritant) (Taken 
from Presti et al., 2015).  
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for 4 weeks with an endpoint of clinical remission determined by CDAI.  No statistical 
difference in clinical remission was achieved despite improvement in CDAI scores 
(Benjamin et al., 2011).  Also, fecal bifidobacteria levels were unchanged.  Interleukin-6 
positive dendritic cells of the lamina propria were demonstrated to be less abundant in 
the FOS treated group as suggested from previously published data (Yeh et al., 2014).  
Hafer et al. (2007) published experiences with a RCT in which lactulose was the 
experimental prebiotic for patients with CD.  No significant difference was found 
between the control and experimental groups. 
 To date, trials studying the efficacy of pre- and probiotics for the treatment of CD 
have been predominantly unsuccessful.  Although in vitro evidence in murine models 
suggests a beneficial role for probiotics, they have been inadequate at inducing clinical 
remission in CD patients.  More research is required in order to discover bacterial species 
that confer a wide range of beneficial properties to the host. 
 
Fecal Microbiota Transplantation 
 Fecal microbiota transplantation (FMT) is not a revolutionary procedure.  The 
concept for FMT in the United States dates back to 1958 when fecal enemas were used as 
an adjunctive therapy in order to treat pseudomembranous enterocolitis, a disease that 
had a 75% mortality rate at the time (Eiseman, 1958).  Literature on the procedure did not 
reappear until 1984 when FMT was utilized to cure Clostridium difficile infection 
(Schwan, 1984).  The mechanism of action of FMT is similar to that of probiotics in that 
healthy bacteria are transplanted into a recipient’s GI tract in order to compete with 
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harmful, inflammation inducing bacteria for a place in the microbiotic niche.  Unlike 
probiotics, which introduce one bacterial strain to a recipient’s gut, FMT aims to 
transplant an immense population of healthy bacteria to the gut.  The return of the 
microbiota to a healthy state is thought to promote an anti-inflammatory environment in 
the gut and hopefully, remission of clinical disease.   
Fecal microbiota transplantation involves the introduction of potentially 
hazardous infectious material into a recipient.  It is important, therein, that a rigorous 
screening process of both the donor and recipient be implemented and followed.  
Consensus among hospitals and centers across the country have detailed a list of potential 
threats to screen for including HIV type 1 and 2, hepatitis A, B and C, Clostridium 
difficile, and Helicobacter pylori amongst others (Brandt, 2013).  Furthermore, ideal 
donors will not have been on an antibiotic course over the previous 3 months as effects 
on the microflora can persist during that time.  Lastly, patients with a history of GI 
disorders such as IBD, Irritable Bowel Syndrome, chronic diarrhea, metabolic syndrome 
etc. should be precluded from donating stool for use in FMT (Mattila et al., 2012).   
 
FMT Preparation and Administration 
There is no universal protocol for the preparation of stool for fecal 
transplantation.  Fresh stool is predominantly reconstituted in saline, water, or milk and 
administered within hours of collection.  The standard minimum amount of fecal matter 
processed is 50 grams (Owens, 2013).  Frozen fecal samples are usually processed in a 
similar fashion to the standard practice utilized at each individual center.  In one study 
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attempting to distinguish a difference between a fresh and frozen sample, samples from 
unknown volunteers were frozen for 1-8 weeks and thawed for approximately 2-4 hours 
(Hamilton, 2012).  Patients with recurrent CDI were administered either fresh or frozen 
samples by colonoscopy and showed no significant difference in remission rate (92% vs. 
90%).  Having a volunteer based collection of pre-screened, frozen FMT samples 
provides a beneficial means to treat time-sensitive cases. 
Modes of administration of FMT have evolved from retention enema to 
colonoscopy and eventually nasogastric/nasojejunal tubes.  Colonoscopy seems to be the 
preferred method for FMT.  Randomized-controlled studies are necessary to determine 
not only the efficacy of the transplantation itself but the best method of administering 
FMT as well. 
 
Fecal Microbiotia Transplantation and Clostridium difficile Infection 
 Clostridium difficile infection affects nearly 500,000 Americans annually, killing 
approximately 29,000 (Lessa et al., 2015).  Dysbiosis of the gut microbiome is a 
prerequisiste for CDI, usually the result of prolonged antibiotic use for an unrelated 
infection (Theriot et al., 2014).  Metagenomic analysis of 16S-RNA-encoding gene 
sequences show a decrease in phylogenetic diversity among the microbiome of CDI 
patients (Chang et al., 2008).  Decreased diversity does not necessarily allow for 
Clostridium difficile invasion, but it is an indication of the dysfunction of the gut to resist 
colonization.  This dysfunction allows for the invasion of Clostridium difficile to take up 
residence in the host.  Clostridium difficile spores produce toxins that disrupt epithelial 
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integrity and stimulate host immune responses resulting in symptomatic CDI (Eckert et 
al., 2015).  Symptoms of CDI are similar to that of CD including diarrhea, abdominal 
pain and inflammatory flare-ups.  With a growing resistance rate and increased 
recurrence rate in antibiotic treated CDI cases (Martin, 2013), FMT has established itself 
as an efficacious and safe treatment.   
In the only published RCT of CDI treated with FMT, 20 patients received a short 
regimen of vancomycin 3 times daily for 3 days followed by infusions of fecal 
suspension via colonoscopy (G. Cammarota et al., 2015).  The control group consisted of 
19 patients receiving vancomycin for 10 days followed by symptom dependent 
vancomycin dosing for 3 weeks.  In the experimental group, 18 patients (90%) reported 
cessation of clinical diarrhea and resolution of CDI for up to 1 year.  The control group 
consisted of only 5 of 19 (26%) patients resolving CDI with cessation of diarrhea.  This 
study found a markedly increased clinical remission rate amongst those receiving FMT 
over the currently standard antibiotic treatment. 
These results verify the findings of a meta-analysis completed in 2013 of 11 peer-
reviewed and published articles attesting to the efficacious potential of FMT for CDI 
patients (Kassam, 2013).  Figure 4 chronicles the results of this meta-analysis.  Methods 
of administering FMT included colonoscopy (7 trials), nasogastric tube (2 trials), and 
naso-jejunal and enema (1 trial each).  Of these trials, only 2 involved completely 
anonymous donors while the rest were patient selected, predominantly consisting of 
relatives.  Results of the meta-analysis showed 245 out of 273 (89.7%) achieved clinical 
remission of CDI dependent on the criteria established by study author.  Modality of 
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FMT exhibited a 10% difference in those administered to the upper GI tract (nasojejunal, 
nasogastric tubes) versus the lower GI tract (colonoscopy, enema) with the lower GI 
administration resulting in more clinical remission.  There was no significant difference 
between patients receiving fecal transplants from anonymous donors versus known 
relatives.  Adverse events were noted in 3 trials in which nasogastric/nasojejunal tubes 
were placed.  Upper gastrointestinal bleeding was noted in one patient who underwent 
nasogastric tube placement (MacConnachie, 2009).  Peritonitis (Aas, 2003) and enteritis 
(Polák et al., 2011) were also found in patients having received FMT via upper 
gastrointestinal means, however, these modalities could not be implicated in the cause of 
such events.  More research is necessary in determining the safest mode of administration 
of FMT. 
The termination of clinical symptoms, chiefly diarrhea, is an important endpoint 
for the treatment of CDI; however, the restoration of the microbiome is essential in 
preventing recurrence of infection.  The microbiome of CDI patients post-FMT has 
indeed been shown to resemble that of the donor feces (Seekatz et al., 2014).  Figure 5 
depicts the shared species between that of a patient pre- and post-FMT, the patient post-
FMT with donor, and the patient pre-FMT with donor.  Both methods of analysis show 
significantly improved similarities in bacterial species between the recipient post-FMT 
and the donor. 
Fecal microbiota transplantation has supplanted antibiotic therapy as a safer and 
more clinically successful means of resolving clinical symptoms of recurrent CDI while 
restoring a healthy host microbiome.  A proof of principle for FMT as an efficacious 
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treatment for CD exists in its utilization against burgeoning CDI.  It is now the “gold 
standard” for treatment of CDI in cases where antibiotics, such as vancomycin and 
metronidazole, have proven unsuccessful.  
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Figure 4:  Results of meta-analysis of peer-reviewed trials using fecal microbiota transplantation 
to treat Clostridium difficile infection (Taken from Kassam et al., 2013). 
 
	   32 
	  
 
 
 
 
 
 
Figure 5: Microbiota species analysis of stool showing similarities between the patient post-FMT 
with donor as compared to the patient pre- and post-FMT as well as the patient pre-FMT with 
donor.  Species richness determined by (A) operational taxonomic units (OTU’s) and (B) the 
Yue-Clayton theta similarity (Taken from Seekatz et al., 2014). 
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Fecal Microbiota Transplantation and Crohn’s Disease  
 Although the successes of FMT in treating CDI over the past decade are an 
exciting indicator of its potential value, there is very little literature on FMT for the 
treatment of Crohn’s disease.  There is a significant lack of randomized-controlled trials 
studying the efficacy of this treatment option.  Cohort studies and case reports have found 
variable results in determining efficacy and present a range of limitations.   
 
Case Studies 
 A case study from Borody et al. (1989) details the improvement of a patient after 
receiving FMT via retention enema.  While the article indicates improvement of 
symptoms 4 months post-FMT without the need for additional medication, limitations on 
the study include unidentifiable parameters for clinical diagnosis and remission, mode 
and frequency of the administration, as well as stool preparation guidelines.   
 Another case report from the West Indies reports a 35-year old women presenting 
to a hospital with bloody diarrhea and abdominal cramps.  Colonoscopy revealed 
Crohn’s-like fistulae and chronic inflammation.  Stool samples were positive for 
Clostridium difficile toxin A and B, and a diagnosis of Crohn’s colitis complicated with 
CDI was made.  The patient did not respond to oral vancomycin, metronidazole, 
mesalazine or steroidal treatment with prednisolone.  FMT was administered via enema 
with only transient success for the first six days.  Repeated FMT was administered when 
diarrhea returned with, still, only marginal success.  A fourth FMT was administered via 
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nasoduodenal tube resulting in resolution of diarrhea and an increased appetite back to 
normal levels.   
 In yet another case report, a 26 year-old man presented to the emergency room on 
two occasions with a perianal fistula (Kao, 2014).  Shortly after recovering with a 
regimen of antibiotics the man returned with a 1-month history of bloody diarrhea, 
weight loss and abdominal pain.  Upon colonoscopy, chronic inflammation of the cecum 
and rectum were observed, and biopsies revealed moderate to severe Crohn’s disease.  
After exhausting numerous treatment options including prednisone, mesalazine, and a 
combined antibiotic therapy of ciprofloxacin and metronidazole, symptoms persisted and 
fecal transplantation was opted for.  The patient received FMT from an anonymous donor 
in a 400mL fecal suspension of 0.9% normal saline via colonoscopy.  Figure 4 is a gross, 
anatomical view of the patient’s cecum attained by colonoscopy pre- and post-FMT.  
Biopsies showed full recovery of mucosal integrity.  Patient reported well-formed bowel 
movements and decrease in abdominal pain up to 4 weeks out from FMT.  Calprotectin, 
an indication of intestinal inflammation, was reduced from 3490µg/g pre-FMT to a more 
normalized 189µg/g post-FMT.   
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Figure 6: Cecal images before (A) and after (B) fecal microbiota transplantation (FMT) (Taken 
from Kao, 2014). 
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Cohort Studies	  
A cohort study of 49 patients with Crohn’s disease who were refractory to all 
other treatment options used single FMT with an adjunctive therapy of mesalazine, a 
common anti-inflammatory drug that is localized to the gut (Cui et al., 2015).  Endpoint 
goals of the study were a reduction in symptoms including diarrhea and abdominal pain, 
decrease in C-reactive protein, and change in Harvey-Bradshaw Index (HBI) of 3 with 
clinical remission indicated with HBI score less than 4.  The HBI is a simplified version 
of the CDAI in which only clinical symptoms are determinants in the overall score and 
disease-state (Harvey & Bradshaw, 1980).  These symptoms, including liquid bowel 
movements, abdominal pain, overall well-being, and bowel mass formation, are subject 
to gradation and scored.  FMT was administered to the mid-gut of all patients via 
gastroscope.  Mesalazine regimen was started 2 weeks pre-FMT and maintained for 3 
months post-FMT then tapered off.  Donors were all relatives of patients and pre-
screened.  Nineteen patients were disregarded for analysis due to complications with C. 
difficile, undefined IBD, or inability to follow-up for 6 months.  Table 4 displays the 
results of the study.  Peak clinical improvement (86.7%) and clinical remission (76.7%) 
via the parameters stated above occurred at the 1-month mark.  At 6 months, 20 of 30 
(66.7%) patients still saw improved symptoms while only 18 of 30 (60%) had HBI scores 
of less than 4.  As far out as 15 months post-FMT, 6 of 7 patients still had improved 
symptoms while 4 of 7 were in remission. 
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 The results of this study show an initial positive efficacy of FMT in alleviating 
symptoms of CD.  The decline in effectiveness could be attributed to the discontinuation 
of mesalazine following the 3-month follow-up.  Despite the decrease in effectiveness 
this study provides a good look at the benefits of FMT.  These patients were all 
unresponsive to traditional therapies including antibiotics, anti-inflammatories and 
steroids.  Fecal transplantation to the mid-gut provided improvement of symptoms, if 
only transiently, to many of the patients in this study. 
 The latest prospective cohort study, conducted in January of 2015 at Seattle 
Children’s Hospital, reported on the findings of 9 pediatric patients with Crohn’s disease 
undergoing fecal microbiota transplantation (Suskind et al., 2015).  Participants in the 
study ranged from 12 to 21-years old and all had pediatric CDAI (PCDAI) scores ranging 
from 10 to 29 indicating mild to moderate severity of disease (Turner et al., 2010).  Of 
the 9 patients, all but one newly diagnosed individual were on treatments prior to FMT.  
These treatments included methotrexate (4 patients), azathioprine (1 patient), mesalazine 
(3 patients), and 5-mercaptopurine (1 patient).  Study endpoints included clinical 
remission with a PCDAI score below 10 and decreased calprotectin and C-reactive 
protein (CRP) levels.  In addition to clinical results, pre- and post-FMT microbiome was 
analyzed for similarity to donor stool samples.  Results of this study can be found in 
Table 5.  Clinical remission was observed at the 2-week follow-up in 7 of 9 patients.  
Mean baseline PCDAI score was 19.7, which dropped to 6.4 at the 2-week time-point and 
8.6 at the 6-week time-point.  Four patients required additional therapy before the study 
reached its endpoint.  Two patients received standard treatment due to flare-ups.   
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FMT Results of Thirty CD Patients in Cohort Study 
	  
Table 3: Results of cohort study of 30 refractory CD patients receiving single FMT with 
adjunctive mesalazine regimen.  Body weight (mean ± SD) (Taken from Cui et al., 2015).
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Table 4: Results of 9 pediatric patients with CD undergoing FMT (Suskind et al., 2015) 
 
 
.
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One patient was placed on metronidazole and infliximab after the 6-week follow-up 
while yet another patient was started on methotrexate and prednisone.  Mean CRP levels 
decreased from 2.4mg/dL to 1.5mg/dL at the 2-week endpoint and remained below 
baseline levels in 5 of 9 patients.  Calprotectin levels saw an initial decline but rose to 
baseline levels by the end of the study in almost all 9 patients.   
 The results of the microbiome analysis showed immediate engraftment 
(measurement of post-FMT microbiome population similarity to donor) in 3 participants, 
gradual engraftment in 4 participants, and no engraftment in 2 participants.  Patient 2 is 
an interesting case in that he achieved clinical remission by week 2 only to see his 
PCDAI score increase to baseline level by studies end.  This patient was 1 of 2 who did 
not achieve donor engraftment.  Patient 18, the other individual who did not achieve 
engraftment, never achieved clinical remission, and while her baseline PCDAI score 
improved over the 12-week study period she had the highest severity of disease at the 
beginning of the study.  Furthermore, the individual with the greatest microbiome 
similarity to donor pre-FMT, patient 18, did not display a positive clinical course 
throughout and needed additional therapeutic intervention.  This is in contrast to patient 1 
who had the most dissimilar microbiome to donor.  This patient’s PCDAI dropped from 
27.5 to 7.5 by week 2 before rising to 10 by the end of the study.  This patient’s CRP and 
calprotectin levels also dropped significantly throughout.  This indicates a possible 
correlation between diversity of patient/donor microbiome and clinical outcome.  Figure 
5 represents 31 microbial species that were detected at greater than 0.1% abundance in 
patients post-FMT that were at less than 0.001% abundance pre-FMT.  Notable bacterial 
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species that saw an uptick in abundance in patients with a positive clinical course in this 
study were of the genus Bifidobacterium and Bacteroides of the phylum Actinobacteria 
and Bacteroidetes, respectively.  As stated above, these bacteria have been known to 
confer beneficial attributes to the gut. 
 The limited availability and reliability of studies reporting on FMT in a CD 
population lends caution to these results.  Further research investigating the potential 
benefits of FMT for CD patients is needed in order to draw conclusions about its possible 
efficacy and safety. 
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Microbial Species Abundance Pre- and Post-FMT 
 
Figure 7: Thirty-one microbial species that were present at less than 0.001% in recipients pre-
FMT that were found to be present at greater than 0.1% in recipients post-FMT (Taken from 
Suskind et al., 2015).
	   43 
 
DISCUSSION 
 
 Crohn’s disease presents difficulty for clinicians and researchers due to its 
unknown etiology and interplay between immunological and microbial inhabitants of the 
gut.  A clear understanding of the principles and mechanisms underlying its manifestation 
are currently being researched and elucidated.  Current management of CD targets the 
resolution of symptoms and the underlying mechanisms of the inflammatory response.  
Symptoms of CD overlap with other inflammatory disorders and infections of the gut 
including ulcerative colitis and CDI.  In this regard, it has been commonplace to use 
similar treatment strategies in order to attain clinical remission of disease.  Recent 
findings of genomic sequencing and genome-wide analysis studies have allowed for the 
cataloging of potential risk loci for CD.  Although 31 of these have been noted as specific 
to CD, there are currently 109 other loci that are described as universal risk factors for 
IBD, particularly CD and UC (Jostins et al., 2012).  Furthermore, other inflammatory 
disorders including psoriasis and ankylosing spondylitis have been implicated as having 
similar risk loci.  These loci can code for mediators of the inflammatory response that can 
affect a wide range of organ systems.  This identifies the phylogenic repercussions of a 
disrupted inflammatory response gene as a major detriment to almost all CD patients.   
The popularity of TNF-α inhibitors in recent years is evidence of the need to 
suppress mediators of the inflammatory response in order to alleviate symptomatic CD.  
Although the meta-analysis by Stidham et al. above produced favorable results to 
standard-care controls, remission and response rates of individual RCTs were 
disappointing towards the ultimate goal of such therapies.  The study that produced the 
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best results in terms of overall clinical remission and response rates was only able to 
induce remission in 35.5% and clinical response (reduction of CDAI score by 100) in 
50% of patients (Hanauer et al., 2006).  Also, all 10 of the RCTs evaluated in the meta-
analysis utilized anti-TNF-α agents adjunctively with baseline medication regimens.  
They all differed in some regard but consisted of a combination therapy of 
immunosuppressants and antibiotics with only one trial administering additional 
probiotics (Sandborn et al., 2011).  This lends to the thought that the antigenic stimulus of 
inflammation is being insufficiently cleared in the gut by the antibiotic regimen 
administered.  Complications with anti-TNF-α agents have been documented in patients 
that require surgery (Zaghiyan, 2015).  Reports have indicated higher post-operative 
infection rates in patients using infliximab.  Also, there have been reports of patients 
gaining infliximab resistance over time (Nagata et al., 2015). 
The ever-growing research dedicated to the classification of the microbiome 
suggests an environmental risk factor involved with CD.  The dysbiotic environment 
usually decreases the number of beneficial bacteria in the gut allowing for the penetration 
of otherwise normal, commensal bacteria across intestinal epithelial cells.  This event in 
genetically susceptible individuals can manifest chronic inflammation.  While dysbiosis 
is a hallmark of CD and CDI alike, the mechanism by which each present symptoms are 
different.  CDI disrupts the integrity of the epithelial cells of the gut via production and 
secretion of toxins, leading to its most prevalent symptom, diarrhea.  In CD, however, 
unbalance of beneficial and harmful bacteria illicit unpredictable results, which in turn 
present with a myriad of symptoms from mild to a severe disease state.  It makes sense, 
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therefore, that a treatment regimen dedicated not only to suppressing the inflammatory 
response but also bettering the overall well being of the microbiome be investigated.   
Antibiotic and probiotic trials in CD patients have proven insufficient in resolving 
chronic inflammation.  Antibiotics function to eliminate harmful bacterial species that 
could be stimulating an inflammatory response.  They also have the capacity to elicit 
their antimicrobial effects on beneficial microbes of the host gut.  In doing so, antibiotics 
can provide space for more harmful and pathogenic bacteria to colonize within the niche 
of the microbiota, which is often the case in CDI.  Fecal microbiota transplantation 
provides an alternative method for re-establishing a healthy bacterial population within 
the gut.  FMT is advantageous in achieving this goal because of its mechanism of 
infiltrating and engrafting within the recipient without providing opportunity for harmful 
bacteria to colonize.  Probiotic use typically consists of the ingestion of large amounts of 
a single bacterial species that can be helpful to the gut microbiota.  In this regard, the 
benefit of a probiotic supplement could be singular depending on its activity.  Figure 3 
showed the ability of some lactobacilli probiotic strains to modulate cytokine secretion, 
however, many strains of the same phyla were unsuccessful in inhibiting TNF-α secretion 
(Presti et al., 2015).  Finding the appropriate bacterial strain to confer a wide range of 
healthy benefits for the host has been challenging.  Moreover, probiotics must be ingested 
in large amounts daily in order to be effective in preserving a healthy gut, and there is a 
serious lack of evidence that suggests curative properties of probiotics (Parra, 2004).  
Successful FMT would be administered once, colonize the gut, and engraft a population 
of diverse, healthy gut flora that can provide all encompassing benefits.   
	   46 
The published literature on experiences with fecal microbiota transplantation for 
Crohn’s disease is extremely limited.  To date, 2 cohort studies and 3 case studies have 
been published.  Suskind et al. were able to show a beneficial clinical course in 7 of 9 
pediatric patients.  FMT was well tolerated in the study and further provided evidence for 
the potential safety and efficacy of this treatment option.  This study was not without 
limitations, however.  As a prospective study with no placebo controlled group the 
possibility for participant bias is a factor.  An aspect of the PCDAI score is subjective in 
nature, which could lead to bias on the part of the patient.  Additionally, the small size of 
the study cannot allow for an accurate conclusion to be made from the results of FMT in 
a CD population.  The cohort study by Cui et al. also demonstrated FMT as a positive 
therapeutic strategy in the treatment of a CD population of 30 individuals.  Although 
clinical remission decreased within the cohort over time, more than 50% of patients who 
reported for the 15-month follow-up were in clinical remission without the need for 
further medication.  One goal of the study was to determine the safety of the mid-gut 
administration of FMT via nasojejunal tube.  No severe adverse events were recorded due 
to use of a gastroscope or endoscopy.  However, this precluded the notion of 
administering FMT to the location of the gut most affected by CD in each individual 
patient.  By this method, targeting the area of the gut most susceptible to chronic 
inflammation was not necessarily achieved.  Again, this cohort study is subject to 
participation bias as all participants were knowingly receiving FMT, which could have 
had an effect on their HBI score.  Long-term follow-up of patients receiving FMTs is also 
necessary in order to ascertain the effects of such a treatment on vital processes of the gut 
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including nutrient absorption and digestion.  Safety regulation agencies are also 
concerned with the lack of long-term studies in determining the overall safety of the 
treatment.  Despite these limitations, FMT has still been shown to be a safe and effective 
short-term treatment for CD patients and warrants further investigation. 
There are several issues that have hampered the advancement of FMT research 
and clinical application.  Firstly, there is no standard protocol for the handling and 
administration of human feces.  To date, hospitals rely on in-house Institutional Review 
Boards (IRBs) to define and standardize their own protocols for the administration of 
FMT (Vyas, 2013).  This includes standardizing donor-screening parameters as well as 
determining potential harms in transplanting possible infectious agents.  More 
importantly, in 2012 The US Food and Drug Association (FDA) classified human feces 
as a biologic therapy and not human tissue, therefore requiring clinicians to file for an 
independent new drug (IND) application in order to treat patients (except for CDI) 
(Ratner, 2014).  This was met with discontent amongst the patient and clinician-
investigator community as the timeline for approval of an IND can take up to 1 month.  
The FDA asserts that due to the unknown long-term effects of such a treatment the IND 
application allows for a certain level of control over who receives an FMT.  The re-
classification of human feces from a drug to an organ would assist in the development of 
stool banks.  Stool banks, such as OpenBiome in Cambridge, Massachusetts, would have 
the ability to provide donor-screened feces for transplantation to patients (Smith, 2014).   
The promising results from trials utilizing FMT in the treatment of Clostridium 
difficile provides an exciting avenue to pursue for IBD researchers and clinicians.  
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Randomized-controlled trials are necessary in determining the efficacy of fecal 
microbiota transplantation as a suitable means for treating Crohn’s disease.  Preliminary 
data from limited resources suggest a beneficial approach to re-establishing a 
homeostatic, healthy environment within the gut of patients with CD.  Additionally, the 
successful trials of anti-inflammatory medications, including TNF-α and alpha-4 integrin 
inhibitors, provides a possible adjunctive therapy to FMT in order to inhibit the 
inflammatory response.  Targeting the microbiome as well as the immune-regulatory 
mechanisms within the gut has the potential to yield never before seen clinical remission 
and response rates within the CD population.  Drug regimens and fecal transplantation 
may not be enough, however, as there is substantial evidence for the role of one’s diet in 
sustaining a healthy microbiota.  It is imperative that particular diet regimens be 
implemented and followed in order to maintain the positive effects that could result from 
any such treatment.
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FUTURE STUDIES 
The need for RCTs for the use of FMT to treat CD is evident.  These trials have 
the capacity to elucidate preferential treatment methods, proper preparation dosages, 
standardized donor-screening techniques, and potential life-threatening side effects.  
Studies using placebo-controlled and standard care-controlled groups will have the ability 
to truly determine the advantages of using FMT.  Furthermore, they can shed light on 
microbe-host interactions that can further help to understand the underlying mechanisms 
that induce chronic inflammation in CD patients.  Genome-wide association studies 
continue to discover the genetic loci by which mutagenic activity can lead to induction of 
disease.  Metagenomic sequencing will further our understanding of the microbes that 
inhabit our gut and their role in disease.  The idea that Crohn’s disease manifests itself 
differently within each patient suggests a need for personalized, patient specific treatment 
options.  By understanding the mechanistic dysfunction in each patient, appropriate drugs 
and medications could be administered on a patient-to-patient basis.  Suskind et al. 
alluded to the idea that recipient-host microbiome dissimilarity could correlate to positive 
FMT results and achieve clinical remission.  In this regard, metagenomic analysis of 
patient and donor microbiomes could help to decide the best possible donor for each 
individual. 
Drug development for IBD in other fields of study is extremely important also.  
Currently, studies investigating siRNA carrying nanoparticles and their ability to silence 
gene transcripts at the point of inflammation are underway (Nielsen et al., 2012).   
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CONCLUSION 
Standard treatment of CD with immunosuppressants, steroids and antibiotics 
achieve clinical remission in only two-thirds of patients.  Anti-inflammatory drugs such 
as infliximab and natalimumab have outperformed standard therapy in randomized trials 
but still fall short of desired remission rates.  Complications involving infection and 
resistance have also been reported with these drugs.  Fecal microbiota transplantation is 
now the “gold standard” treatment for patients with CDI who are refractory to antibiotics.  
Preliminary data from studies using FMT for the treatment of CD are promising but 
extremely limited.  Further investigation of this modality is required in order to determine 
its possible efficacy for Crohn’s disease. 
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  Reaction	  
o Cell-­‐Mediated	  Lympholysis	  
	   	   	   	  
	   	  
	  
	   71 
Teaching/Mentorship	  
	  
Fall	  2014	   	   Teaching	  Assistant	  	  
o Biochemistry/Cell	  biology	  course	  in	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